Leerink Partnrs Has Optimistic Outlook of ELAN Q3 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Investment analysts at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for Elanco Animal Health in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst D. Clark now anticipates that the company will earn $0.14 per share for the quarter, up from their previous forecast of $0.11. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's Q4 2025 earnings at $0.14 EPS and FY2025 earnings at $0.84 EPS.

A number of other analysts have also weighed in on the stock. Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Piper Sandler reduced their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Stifel Nicolaus boosted their target price on Elanco Animal Health from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Morgan Stanley reduced their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 26th. Finally, UBS Group reduced their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of "Hold" and a consensus price target of $15.00.

Elanco Animal Health Trading Down 1.1%

Shares of NYSE ELAN traded down $0.14 during mid-day trading on Monday, hitting $12.88. The stock had a trading volume of 6,545,420 shares, compared to its average volume of 5,025,733. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $18.80. The business has a 50 day moving average price of $9.97 and a two-hundred day moving average price of $11.43. The firm has a market cap of $6.40 billion, a P/E ratio of 32.20, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.34 EPS.

Institutional Trading of Elanco Animal Health

Institutional investors have recently bought and sold shares of the company. Allworth Financial LP grew its position in Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Elanco Animal Health in the 3rd quarter worth approximately $35,000. CoreCap Advisors LLC purchased a new position in Elanco Animal Health in the 4th quarter worth approximately $29,000. Parallel Advisors LLC raised its holdings in Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after acquiring an additional 1,852 shares during the last quarter. Finally, NBC Securities Inc. purchased a new position in Elanco Animal Health in the 1st quarter worth approximately $40,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares of the company's stock, valued at $1,136,881.80. This represents a 9.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.89% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.